SYNDAX PHARMACEUTICALS, INC. <SNDX.O>: UBS CUTS TARGET PRICE TO $33 FROM $37

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Trade smarter